Crossmark

Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis

Crossref DOI link: https://doi.org/10.1007/s10549-026-07971-z

Published Online: 2026-04-17

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tam, Grace

Waddell, Donald

Freeman, Jincong Q.

Chen, Nan

Yang, Heng
Funding

Funding for this research was provided by:

Susan G. Komen

National Institute on Aging
License Information

Text and Data Mining valid from 2026-04-17

Version of Record valid from 2026-04-17
More Information

Article History

Received: 26 November 2025

Accepted: 6 April 2026

First Online: 17 April 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below